Pharm-Olam was selected by the US Department of Defense to run a mid-to late-stage trial of blockbuster autoimmune and inflammation drug adalimumab, knonw as AbbVie’s Humira.
Rankings by 
Национальный рейтинг
454th
in United StatesРегиональный рейтинг
515th
in North America and CaribbeanГлобальный рейтинг
1246th
worldwide